[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"AgelessRx\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":45},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":5},"100600063",false,"NCT07092618","Effectiveness of Alternative Therapies in Maintaining Weight Loss Achieved by GLP-1 Medications Post-Cessation","Effectiveness of Alternative Therapies in Maintaining Weight Loss Achieved by GLP-1 Medications Post-Cessation: A Randomized, Controlled Trial","Inclusion Criteria:\n\n* Existing AgelessRx patient\n* Adults (40 - 85 years of age)\n* Any sex\n* Any ethnicity\n* BMI ≥ 22 kg\u002Fm\\^2\n* Have been on GLP-1s (Wegovy, Ozempic, or a compounded form of GLP-1s) for at least three months before study initiation\n* Have lost at least 15 lbs during their GLP-1 use\n\nExclusion Criteria:\n\n* Individuals who are denied a longevity product by the AgelessRx medical team will not be asked to participate in any product specific test(s) or questionnaire(s)\n* History of bariatric surgery\n* Use of weight-loss medications other than GLP-1s within the past 6 months\n* Age \\\u003C40 years\n* Contraindications to naltrexone, metformin, or rapamycin\n* Significant psychiatric illness that may affect participation\n* Pregnant or breastfeeding individuals","ALL","40 Years","85 Years",{"count":19,"type":20},150,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE2","PHASE3","The goal of this randomized, controlled trial is to evaluate the effectiveness of alternative therapies (metformin alone, with rapamycin, and with low-dose naltrexone) in maintaining weight loss in patients weaning off GLP-1 medications.\n\nThe main questions it aims to answer are:\n\n* Whether the combination of metformin, with or without rapamycin or low-dose naltrexone, will be adequate to maintain the relative weight of individuals gradually discontinuing GLP-1 receptor agonist use.\n* Whether individuals discontinuing GLP-1 receptor agonist use who instead use a combination of metformin, with or without rapamycin or low-dose naltrexone, will experience less weight regain over the course of six months post-cessation than those who do not use any alternative medications.\n\nResearchers will compare the four groups: 1) control, 2) metformin, 3) metformin + rapamycin, and 4) metformin + low-dose naltrexone, to assess changes in the percentage of weight regain, metabolic indicators (e.g., HbA1c, lipid profile), and quality of life PROs, six months after cessation of GLP-1 therapy.\n\nParticipants will:\n\n* Administer the assigned intervention following a dosing and administration protocol provided by the study and medical team.\n* Complete a medical intake for overall health status, medical history and demographic information,\n* Complete patient-reported outcomes\u002Fsurveys and assessments\n* Complete blood work at baseline and every 16 weeks thereafter to measure CBC, CMP, and standard health biomarker panels (e.g., cholesterol, glucose, creatinine, sodium, potassium).\n* Share data from health wearables with the research team throughout the study to improve the accuracy of evaluating activity, sleep, heart rate, and other related healthspan measures.",[27,28,29,30],"Longevity","GLP-1","Geroscience","Aging",[27,30,32,28],"Healthy Aging","RECRUITING","2025-07-28",{"date":36,"type":37},"2025-07-30","ACTUAL",{"date":39,"type":37},"2024-12-17",{"date":41,"type":20},"2025-08",{"name":43,"class":44},"AgelessRx","INDUSTRY",""]